Yes, it will take longer for that data, which may confirm whether our therapy will halt and/or maybe to some extent reverse loss of central vision for late stage RP11 sufferers. A robust safety profile is a must and early insights into efficacy IMO do support increased conviction that we are likely on the right track overall, the later part will be cleared up over time as the hierarchal pathway towards registrational approval unfolds. I thought that was/is fairly obvious, but maybe not. No ramping intended, just very chuffed to see us making progress to the extent that we are.
PYC Price at posting:
10.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)